Anti-SARS-CoV-2 Antibody Development over Four Years in Blood Donors
Viruses · 2025
DOI: 10.3390/v17101292 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Christoph Niederhauser und 9 weiteren Autor:innen. Beteiligte Einrichtung: Interregional Blood Transfusion SRC, 3008 Bern, Switzerland. Hauptthemen laut MEDLINE: Blood Donors, Antibodies, Viral, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Humanitarian Foundation of the Swiss Red Cross.
Abstract (Originalsprache)
The blood donor population has great potential to serve as a sentinel system for the general population. The data presented in this study of a survey of the seroprevalence of Anti-SARS-CoV-2 antibodies in Switzerland are an illustrative example of this possibility. From March 2020 to January 2021, the increase in antibody seroprevalence for both Anti-NCP and Anti-S was only very moderate, up to ~17%. In May/June 2021, the Anti-NCP seroprevalence was 21.6% and the S-seroprevalence 59.4%, respectively, indicating only a moderate natural infection rate. The Anti-seroprevalence rate was in good agreement with the first vaccination campaign launched in winter 2020/21. The dramatic increase in the antibodies against the NCP protein (74.6%) since November/December 2021 to June–August 2022 was simultaneous with the appearance and rapid spread of the Omicron SARS-CoV-2 variant in Switzerland and the abolition of compulsory mask wearing in public spaces. At the end of 2022, 99.0% of the blood donor population already developed antibodies against the S protein and 83.9% against the NCP. One year later, after the official termination of the pandemic, these seroprevalences were even higher, 99.8% for the Anti-S and 95.0% for Anti-NCP. This increase for both of them was in accordance with the vaccination campaigns, the abolition of mask wearing, and the spread of the Omicron variant. These data show how the blood donor population can be used to represent the infection surveillance of the general population of a region or country.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interregional Blood Transfusion SRC, 3008 Bern, Switzerland.
- Institute of Infectious Diseases, University of Bern, 3001 Bern, Switzerland.
- Faculty of Biological Medicine, Lausanne University Hospital, 1005 Lausanne, Switzerland.
- Blood Transfusion Service SRC Della Svizzera Italiana, 6900 Lugano, Switzerland.
- Blood Transfusion Service SRC Beider Basel, 4031 Basel, Switzerland.
- Blood Transfusion Service SRC Genève, 1211 Genève, Switzerland.
ORCID-Profile: Christoph Niederhauser, Andreas Buser
Förderung
- Humanitarian Foundation of the Swiss Red Cross
Zitieren
APA
Niederhauser, C., Widmer, N., Tinguely, C., Suter Riniker, F., Fontana, S., Buser, A., Waldvogel, S., Thierbach, J., Züger, M., & Gowland, P. (2025). Anti-SARS-CoV-2 Antibody Development over Four Years in Blood Donors. Viruses. https://doi.org/10.3390/v17101292
Vancouver
Niederhauser C, Widmer N, Tinguely C, Suter Riniker F, Fontana S, Buser A, et al. Anti-SARS-CoV-2 Antibody Development over Four Years in Blood Donors. Viruses. 2025. doi:10.3390/v17101292
BibTeX
@article{Niederhauser2025,
author = {Niederhauser, Christoph and Widmer, Nadja and Tinguely, Caroline and Suter Riniker, Franziska and Fontana, Stefano and Buser, Andreas and Waldvogel, Sophie and Thierbach, Jutta and Züger, Max and Gowland, Peter},
title = {Anti-SARS-CoV-2 Antibody Development over Four Years in Blood Donors},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17101292}
}
EUVIMED